About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Publications
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dodekin
Dekavil
OncoFAP Radio Conjugates (Imaging)
OncoFAP Radio Conjugates (Therapy)
OncoFAP-GlyPro-MMAE (Therapy)
OncoACP3 (Imaging)
OncoACP3 (Therapy)
OncoCAIX
Press Releases & Media
Press Releases
Events
Media Library
Philogen in the news
Work with us
Careers
Partnering
Investors
Investor Relations
Shareholding
IPO
Press Releases
Financial Statements
Financial Calendar
Internal Dealing
Buyback
Analyst Coverage
Webinars
IR Contacts
Governance
Board of Directors
Board of Statutory Auditors
Documents & Procedures
Shareholders’ Meetings
Codice etico e Modello 231
Sustainability (ESG)
Governance
Investors
About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Publications
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dodekin
Dekavil
OncoFAP Radio Conjugates (Imaging)
OncoFAP Radio Conjugates (Therapy)
OncoFAP-GlyPro-MMAE (Therapy)
OncoACP3 (Imaging)
OncoACP3 (Therapy)
OncoCAIX
Press Releases & Media
Press Releases
Events
Philogen in the news
Media Library
Work with us
Careers
Partnering
Home
$
Investors
$
Buyback-test
Buyback-test
Investor Relations
Shareholding
IPO
Corporate Presentation
Press Releases
Internal Dealing
Buyback
Financial Statements
Financial Calendar
Analyst Coverage
Webinars
IR Contacts
I programma di acquisto azioni proprie 2021
II programma di acquisto azioni proprie 2023
III programma di acquisto azioni proprie 2024
IV programma di acquisto azioni proprie 2025
V programma di acquisto azioni proprie 2026
